Remembering when bankers tried to overthrow FDR and install a fascist dictator

Yes, a coup d'état.

FDR
Image source: History Archive / Universal Images Group via Getty Images
  • Though we know today that his policies eventually ended the Great Depression, FDR's election was seen as disastrous by some.
  • A group of wealthy bankers decided to take things into their own hands; they plotted a coup against FDR, hoping to install a fascist dictator in its stead.
  • Ultimately, the coup was brought to light by General Smedley Butler and squashed before it could get off the ground.

When we look back at history, we have the benefit of knowing how things turned out. Not true for those who were living through history's tensest moments. At key inflection points in history and in response to crises, most of the actors had no idea what would happen or what the right thing to do was. Sometimes, this uncertainty drove people to bold and ill-advised actions.

Take the Great Depression. Something had to be done, but nobody knew what for certain. When Franklin Delano Roosevelt was elected on a campaign that promised to abandon the gold standard and provide government jobs for the unemployed, many in the grips of the crisis thought that this was certainly the wrong way to go.

"This is despotism, this is tyranny, this is the annihilation of liberty," wrote Republican Senator Henry D. Hatfield of West Virginia to a colleague. "The ordinary American is thus reduced to the status of a robot. The president has not merely signed the death warrant of democracy but has ordained the mutilation of the Constitution, unless the friends of liberty, regardless of party, band themselves together to regain their lost freedom."

The allure of fascism

Fascism had reared its head in Europe, and the world had yet to make up its mind what it thought about it. That would come later, in World War II. Many thought that the best way to pull America out of the Great Depression was to install a dictator. Even the New York Herald Tribune ran a headline called "For Dictatorship If Necessary." Although the newspaper's article was in support of FDR, a group of wealthy financiers believed that America should indeed have a dictator, just not in the form of FDR, a suspected communist. So, they began to plot a coup d'état that would later come to be known as the Business Plot, or the Wall Street Putsch.

The conspirators included Gerald MacGuire, a bond salesman; Bill Doyle, commander of the Massachusetts American Legion; investment banker Prescott Bush, the father of George H. W. Bush and grandfather of George W. Bush; and others.

The Business Plot nearly involved another individual as well: Retired Major General Smedley Butler, who was at that time the most decorated soldier in U.S. history. After his military career, however, Butler became a vociferous critic of war and its place in American capitalism. Later, he would write the famous War is a Racket and an article in the socialist magazine Common Sense stating, "I spent most of my time as a high-class muscle man for Big Business, for Wall Street and the bankers. In short, I was a racketeer, a gangster for capitalism."

Butler was also an influential figure in the so-called Bonus Army, a group of 43,000 marchers — among them many World War I veterans — who were camped at Washington to demand the early payment of the veteran's bonus promised to them for their service. Although his politics leaned more to the left than the Business Plot conspirators would like, Butler was extremely well-respected among veterans and the military, who, like everybody else, were fed up. What's more, MacGuire believed that Butler could be more easily manipulated than other generals. And the conspirators needed a general.

The members of the Business Plot set up several meetings with Butler where they not-so-gradually informed him of their plan. The conspirators would provide the financial backing and recruit an army of 500,000 soldiers, which Butler was to lead. The pretext for the coup would be that FDR's health was failing. FDR would remain in a ceremonial position, in which, as MacGuire allegedly described, "The President will go around and christen babies and dedicate bridges and kiss children." The real power of the government would be held in the hands of a Secretary of General Affairs, who would be in effect a dictator: "somebody to take over the details of the office — take them off the President's shoulders. … A sort of a super secretary."

General Smedley Butler. Image source: Wikimedia Commons

Quashing the Business Plot

However, Butler was not so willing a compatriot as they had originally suspected. After meeting with the men several times and learning of the extent of their plan, Butler went to Congress to expose them as traitors. When news broke, nobody really believed that such a coup attempt could even be considered, let alone planned or put into action. In fact, the New York Times's initial reporting on the subject was full of quotes like "Perfect moonshine!", "A fantasy!", and "It's a joke — a publicity stunt." A second article from the New York Times's on the topic was titled "Credulity Unlimited."

Initially, Congress's reaction was similar, but with Butler's testimony; the testimony of reporter Paul French, who was present at one of Butler's meetings with MacGuire; and MacGuire's own unconvincing testimony, they began to take it more seriously and investigated the subject.

Ultimately, the Congressional investigation found that Butler was telling the truth: the seeds of a coup had indeed been planted. But Congress's perspective was that the plot had little chance of getting off the ground at all — rather, it had been, in the words of Mayor La Guardia of New York, "a cocktail putsch."

Nobody was prosecuted in the plot. In fact, some later went on to serve in office, such as Prescott Bush. Would the coup have been carried out had Butler merely turned down MacGuire's offer, rather than report them to Congress? It's impossible to say. But the Wall Street Putsch does show that dire times can drive people to make otherwise inconceivable — "moonshine" — plans.

U.S. Navy controls inventions that claim to change "fabric of reality"

Inventions with revolutionary potential made by a mysterious aerospace engineer for the U.S. Navy come to light.

U.S. Navy ships

Credit: Getty Images
Surprising Science
  • U.S. Navy holds patents for enigmatic inventions by aerospace engineer Dr. Salvatore Pais.
  • Pais came up with technology that can "engineer" reality, devising an ultrafast craft, a fusion reactor, and more.
  • While mostly theoretical at this point, the inventions could transform energy, space, and military sectors.
Keep reading Show less

Why so gassy? Mysterious methane detected on Saturn’s moon

Scientists do not know what is causing the overabundance of the gas.

An impression of NASA's Cassini spacecraft flying through a water plume on the surface of Saturn's moon Enceladus.

Credit: NASA
Surprising Science
  • A new study looked to understand the source of methane on Saturn's moon Enceladus.
  • The scientists used computer models with data from the Cassini spacecraft.
  • The explanation could lie in alien organisms or non-biological processes.
Keep reading Show less

CRISPR therapy cures first genetic disorder inside the body

It marks a breakthrough in using gene editing to treat diseases.

Credit: National Cancer Institute via Unsplash
Technology & Innovation

This article was originally published by our sister site, Freethink.

For the first time, researchers appear to have effectively treated a genetic disorder by directly injecting a CRISPR therapy into patients' bloodstreams — overcoming one of the biggest hurdles to curing diseases with the gene editing technology.

The therapy appears to be astonishingly effective, editing nearly every cell in the liver to stop a disease-causing mutation.

The challenge: CRISPR gives us the ability to correct genetic mutations, and given that such mutations are responsible for more than 6,000 human diseases, the tech has the potential to dramatically improve human health.

One way to use CRISPR to treat diseases is to remove affected cells from a patient, edit out the mutation in the lab, and place the cells back in the body to replicate — that's how one team functionally cured people with the blood disorder sickle cell anemia, editing and then infusing bone marrow cells.

Bone marrow is a special case, though, and many mutations cause disease in organs that are harder to fix.

Another option is to insert the CRISPR system itself into the body so that it can make edits directly in the affected organs (that's only been attempted once, in an ongoing study in which people had a CRISPR therapy injected into their eyes to treat a rare vision disorder).

Injecting a CRISPR therapy right into the bloodstream has been a problem, though, because the therapy has to find the right cells to edit. An inherited mutation will be in the DNA of every cell of your body, but if it only causes disease in the liver, you don't want your therapy being used up in the pancreas or kidneys.

A new CRISPR therapy: Now, researchers from Intellia Therapeutics and Regeneron Pharmaceuticals have demonstrated for the first time that a CRISPR therapy delivered into the bloodstream can travel to desired tissues to make edits.

We can overcome one of the biggest challenges with applying CRISPR clinically.

—JENNIFER DOUDNA

"This is a major milestone for patients," Jennifer Doudna, co-developer of CRISPR, who wasn't involved in the trial, told NPR.

"While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place," she continued.

What they did: During a phase 1 clinical trial, Intellia researchers injected a CRISPR therapy dubbed NTLA-2001 into the bloodstreams of six people with a rare, potentially fatal genetic disorder called transthyretin amyloidosis.

The livers of people with transthyretin amyloidosis produce a destructive protein, and the CRISPR therapy was designed to target the gene that makes the protein and halt its production. After just one injection of NTLA-2001, the three patients given a higher dose saw their levels of the protein drop by 80% to 96%.

A better option: The CRISPR therapy produced only mild adverse effects and did lower the protein levels, but we don't know yet if the effect will be permanent. It'll also be a few months before we know if the therapy can alleviate the symptoms of transthyretin amyloidosis.

This is a wonderful day for the future of gene-editing as a medicine.

—FYODOR URNOV

If everything goes as hoped, though, NTLA-2001 could one day offer a better treatment option for transthyretin amyloidosis than a currently approved medication, patisiran, which only reduces toxic protein levels by 81% and must be injected regularly.

Looking ahead: Even more exciting than NTLA-2001's potential impact on transthyretin amyloidosis, though, is the knowledge that we may be able to use CRISPR injections to treat other genetic disorders that are difficult to target directly, such as heart or brain diseases.

"This is a wonderful day for the future of gene-editing as a medicine," Fyodor Urnov, a UC Berkeley professor of genetics, who wasn't involved in the trial, told NPR. "We as a species are watching this remarkable new show called: our gene-edited future."

Quantcast